David Kirske - 29 Dec 2022 Form 4 Insider Report for CTI BIOPHARMA CORP

Role
EVP, Chief Financial Officer
Signature
David Kirske
Issuer symbol
N/A
Transactions as of
29 Dec 2022
Net transactions value
-$272,190
Form type
4
Filing time
03 Jan 2023, 17:36:52 UTC
Previous filing
06 Oct 2022
Next filing
16 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTIC common stock Options Exercise $12,501 +13,174 +78% $0.9489 30,087 29 Dec 2022 Direct
transaction CTIC common stock Sale $79,044 -13,174 -44% $6.00 16,913 29 Dec 2022 Direct F1
transaction CTIC common stock Award $1,093 +214 +1.3% $5.11 17,127 30 Dec 2022 Direct F2
transaction CTIC common stock Options Exercise $11,387 +12,000 +70% $0.9489 29,127 30 Dec 2022 Direct
transaction CTIC common stock Sale $72,000 -12,000 -41% $6.00 17,127 30 Dec 2022 Direct F1
transaction CTIC common stock Options Exercise $759 +800 +4.7% $0.9489 17,927 30 Dec 2022 Direct
transaction CTIC common stock Sale $4,804 -800 -4.5% $6.00 17,127 30 Dec 2022 Direct F1
transaction CTIC common stock Options Exercise $993 +1,047 +6.1% $0.9489 18,174 30 Dec 2022 Direct
transaction CTIC common stock Sale $6,292 -1,047 -5.8% $6.01 17,127 30 Dec 2022 Direct F1
transaction CTIC common stock Options Exercise $25,640 +27,021 +158% $0.9489 44,148 03 Jan 2023 Direct
transaction CTIC common stock Sale $162,423 -27,021 -61% $6.01 17,127 03 Jan 2023 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -13,174 -4.1% $0.000000 311,084 29 Dec 2022 Common Stock 13,174 $0.9489 Direct F4
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -12,000 -3.9% $0.000000 299,084 30 Dec 2022 Common Stock 12,000 $0.9489 Direct F4
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -800 -0.27% $0.000000 298,284 30 Dec 2022 Common Stock 800 $0.9489 Direct F4
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -1,047 -0.35% $0.000000 297,237 30 Dec 2022 Common Stock 1,047 $0.9489 Direct F4
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -27,021 -9.1% $0.000000 270,216 03 Jan 2023 Common Stock 27,021 $0.9489 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person.
F2 Shares acquired under the CTI BioPharma Corp. 2007 Employee Stock Purchase Plan.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.07, inclusive. The reporting person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
F4 One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022.